Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma

This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies. The study will assess changes in HIF2-regulated gene expression through RNA sequencing of serial tumor biopsies obtained at baseline, during treatment, and at progression. Blood samples will also be collected for future analyses.

NCT Number	NCT07748988
Lead Sponsor	Vanderbilt-Ingram Cancer Center Collaborators: Arcus Biosciences, Inc.
Conditions	Refractory Renal Cell Carcinoma
Enrollment	12 participants
Start Date	2029-07-01
Primary Completion	2030-07-01 (estimated)
Study Completion	2031-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-06